KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme Group (CME) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Cme Group (CME) over the last 17 years, with Sep 2025 value amounting to $2.4 billion.

  • Cme Group's Cash & Equivalents rose 5.37% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 5.37%. This contributed to the annual value of $2.9 billion for FY2024, which is 0.67% down from last year.
  • Cme Group's Cash & Equivalents amounted to $2.4 billion in Q3 2025, which was up 23.49% from $2.0 billion recorded in Q2 2025.
  • Cme Group's 5-year Cash & Equivalents high stood at $2.9 billion for Q4 2023, and its period low was $936.4 million during Q1 2021.
  • In the last 3 years, Cme Group's Cash & Equivalents had a median value of $2.0 billion in 2025 and averaged $2.1 billion.
  • Per our database at Business Quant, Cme Group's Cash & Equivalents skyrocketed by 118.46% in 2022 and then dropped by 23.49% in 2023.
  • Cme Group's Cash & Equivalents (Quarterly) stood at $2.8 billion in 2021, then declined by 4.05% to $2.7 billion in 2022, then grew by 7.05% to $2.9 billion in 2023, then declined by 0.67% to $2.9 billion in 2024, then rose by 5.37% to $2.4 billion in 2025.
  • Its Cash & Equivalents was $2.4 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $1.4 billion in Q1 2025.